Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Menasché, P
Right arrow Articles by Desnos, M
Right arrow Search for Related Content
PubMed
Right arrow Articles by Menasché, P
Right arrow Articles by Desnos, M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Cardiac reparation: fixing the heart with cells, new vessels and genes

P Menasché*,1 and M Desnos2

a Department of Cardiovascular Surgery, Hôpital Bichat Claude Bernard, Paris, France
b Départment of Cardiology, Hôpital, Européen Georges Pompidou and Taculté de Médecine Necker-Enfants Malades, Paris, France

* Correspondence: Dr Philippe Menasché, Department of Cardiovascular Surgery, Hopital Bichat Claude Bernard, 46, rue Henri Huchard, 75018 Paris, France.

Abstract

Cell-based interventions, angiogenesis and gene therapy are among the newest treatment modalities that have been proposed to improve outcomes in patients with ischaemic heart disease. Experimental data have established that implantation of contractile cells into fibrous post-infarction scars can allow those tissues to regain some functionality. Although clinical data are still preliminary, they support the concept of cell transplantation and raise realistic hopes that it will find a place among strategies to ameliorate heart failure in the future. Therapeutic angiogenesis is another promising means of ameliorating ischaemic symptoms as there is already experimental evidence that angiogenic growth factors can stimulate the development of functionally significant new blood supply. In addition, successful correction of major abnormalities of calcium cycling by adenoviral gene transfer represents an encouraging finding in gene therapy. However, the complexity of gene dysregulation that is involved in heart failure complicates identification of the culprit genes, and important safety issues remain to be addressed before such therapies may proceed to clinical trials.

Key Words: Angiogenesis • cellular transplantation • gene therapy • heart failure

References

  1. Berry C, Murdoch D, McMurray J. Economics of chronic heart failure. Eur J Heart Fail. 2001;3:283–291[Abstract/Free Full Text]
  2. Stewart S, MacIntyre K, Hole D, Capewell S, McMurray JJ. More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001;3:315–322[Abstract/Free Full Text]
  3. Soonpaa MH, Field LJ. Survey of studies examining mammalian cardiomyocyte DNA synthesis. Circ Res. 1998;83:15–26[Free Full Text]
  4. Kajstura J, Ler A, Finato N, Di Loreto C, Beltrami CA. Myocyte proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci USA. 2nd Edition. 1998. p. 8801–8805
  5. Beltrami AP, Urbanek K, Kajstura J, et al. Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med. 2001;344:1750–1757[Abstract/Free Full Text]
  6. Williams RS. Cell cycle control in the terminally differentiated myocyte. Cardiol Clin. 1998;16:739–754[CrossRef][Medline]
  7. Tam SKC, Gu W, Nadal-Ginard B, Vlahakes GJ. Molecular cardiomyoplasty: potential cardiac gene therapy for chronic heart failure. J Thorac Cardiovasc Surg. 1995;109:918–924[Abstract]
  8. Yoo KJ, Li RK, Weisel RD, et al. Heart cell transplantation improves heart function in dilated cardiomyopathic hamsters. Circulation. 2000;102(suppl III):III–204.9
  9. Ohno N, Li RK, Weisel RD, Mickle DAG, Yoo KJ. Cryopreserved cell transplantation into the myocardium of dilated cardiomyopathic hamsters: a comparison of three cell types. [abstract]Circulation. 2000;102(suppl II):II–650
  10. Scorsin M, Hagöge AA, Dolizy I, et al. Can cellular transplantation improve function in doxorubicin-induced heart failure? Circulation. 1998;98(suppl II):II–151.6
  11. El Oakley RM, Ooi OC, Bongso A, Yacoub MH. Myocyte transplantation for myocardial repair: a few good cells can mend a broken heart. Ann Thorac Surg. 2001;71:1724–1733[Abstract/Free Full Text]
  12. Leor J, Patterson M, Quinones MJ, Kedes LH, Kloner RA. Transplantation of fetal myocardial tissue into the infarcted myocardium of rat. Circulation. 1996;94(suppl II):II–332.6
  13. Scorsin M, Hagöge AA, Marotte F, et al. Does transplantation of cardiomyocytes improve function of infarcted myocardium. Circulation. 1997;96(suppl II):II–188.93
  14. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD. Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest. 1996;98:2512–2523[Web of Science][Medline]
  15. Chiu RC-J, Zibaitis A, Kao RE. Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation. Ann Thorac Surg. 1995;60:12–18[Abstract/Free Full Text]
  16. Watanabe E, Smith DMJ, Delearpio JB, et al. Cardiomyocyte transplantation in a porcine myocardial infarction model. Cell Transplant. 1998;7:239–246[CrossRef][Web of Science][Medline]
  17. Reinecke H, MacDonald GH, Hauschka SD, Murry CE. Electromechanical coupling between skeletal and cardiac muscle: implications for infarct repair. J Cell Biol. 2000;149:731–740[Abstract/Free Full Text]
  18. Li R-K, Jia Z-Q, Weisel RD, et al. Cardiomyocyte transplantation improves heart function. Ann Thorac Surg. 1996;62:654–661[Abstract/Free Full Text]
  19. Kao RE, Chin TK, Ganote CE, Hossler FE, Li C, Browder W. Satellite cell transplantation to repair injured myocardium. Cardiac Vase Regeneration. 2000;1:31–42
  20. Taylor DA, Atkins BZ, Hungspreugs P, et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med. 1998;4:929–933[CrossRef][Web of Science][Medline]
  21. Rajnoch C, Chachques J-C, Berrebi A, Bruneval P, Benoit M-O, Carpentier A. Cellular therapy reverses myocardial dysfunction. J Theme Cardiovasc Surg. 2001;121:871–878[CrossRef]
  22. Jain M, DerSimonian H, Brenner DA, et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation. 2001;103:1920–1927[Abstract/Free Full Text]
  23. Pouzet B, Ghostine S, Vilquin J-T, et al. Is skeletal myoblast transplantation clinically relevant in the era of angiotensinconverting enzyme inhibitors. [abstract]Circulation. 2000;102(suppl II):II–682
  24. Pouzet B, Vilquin J-T, Hagöge AA, et al. Factors affecting functional outcome after autologous skeletal myoblast transplantation. Ann Thorac Surg. 2001;71:844–851[Abstract/Free Full Text]
  25. Hutcheson KA, Atkins BZ, Hueman MT, Hopkins MB, Glower DD, Taylor DA. Comparison of benefits on myocardial performance of cellular cardiomyoplasty with skeletal myoblasts and fibroblasts. Cell Transplant. 2000;9:359–368[Web of Science][Medline]
  26. Sakai T, Li R-K, Weisel RD, et al. Fetal cell transplantation: a comparison of three cell types. J Thorac Cardiovasc Surg. 1999;118:715–725[Abstract/Free Full Text]
  27. Reinecke H, Murry CE. Transmittal replacement of myocardium after skeletal myoblast grafting into the heart: too much of a good thing? Cardiovasc Pathol. 2000;9:337–344[CrossRef][Web of Science][Medline]
  28. Scorsin M, Hagöge AA, Vilquin J-T, et al. Comparison of the effects of fetal cardiomyocytes and skeletal myoblast transplantation on postinfarction left ventricular function. J Thorac Cardiovasc Surg. 2000;119:1169–1175[Abstract/Free Full Text]
  29. Suzuki K, Brand NJ, Kahn MA, Farrell AO, Yacoub MH. Creation of a skeletal myoblast cell line overexpressing connexin 43- as a novel strategy for cell transplantation to the heart. [abstract]J Heart Lung Transplant. 2000;19:69
  30. Tanabe T, Mikami A, Numa S, Beam KG. Cardiac-type excitation-contraction coupling in dysgenic skeletal muscle injected with cardiac dihydropyridine receptor cDNA. Nature. 1990;344:451–453[CrossRef][Medline]
  31. Wang JS, Shum-Tim D, Galipeau J, Chedrawy E, Eliopoulos N, Chin RCJ. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac Cardiovasc Surg. 2000;120:999–1006[Abstract/Free Full Text]
  32. Orlic D, Kajstura J, Chimend S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701–705[CrossRef][Medline]
  33. Robinson SW, Cho PW, Levitsky HI, et al. Arterial delivery of genetically labelled skeletal myoblasts to the routine heart: longterm survival and phenotypic modification of implanted myoblasts. Cell Transplant. 1996;5:77–91[Web of Science][Medline]
  34. Suzuki K, Brand NJ, Smolenski RT, Jayakumar J, Murtuza B, Yacoub MH. Development of a novel method for cell transplantation through the coronary artery. Circulation. 2000;102(suppl III):III–359.64
  35. Suzuki K, Smolenski RT, Jayakumar J, Murtuza B, Brand NJ, Yacoub MH. Heat shock treatment enhances graft cell survival in skeletal myoblast transplantation to the heart. Circulation. 2000;102(suppl III):III–216.21
  36. Li RK, Yau TM, Weisel RD, et al. Construction of a bioengineered cardiac graft.). J Thorac Cardiovasc Surg. 2000;119:368–375[Abstract/Free Full Text]
  37. Sakai T, Li RK, Weisel RD, et al. The fate of a tissue-engineered cardiac graft in the right ventricular outflow tract of the rat. J Thorac Cardiovasc Surg. 2001;121:932–942[Abstract/Free Full Text]
  38. Chu V, Kuang J-Q, McGinn A, Giaid A, Korkola S, Chin RC-J. Angiogenic response induced by mechanical transmyocardial revascularization. J Thorac Cardiovasc Surg. 1999;118:849–856[Abstract/Free Full Text]
  39. Suzuki K, Murtuza B, Sammut IA, Suzuki N, Smolenski RT. Refinement of cell transplantation to the heart by using VEGF-overexpressing skeletal myoblasts. [abstract]Circulation. 2000;102(suppl II):II–651
  40. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium. Deleterious effects of unregulated expression. Circulation. 2000;102:898–901[Abstract/Free Full Text]
  41. Menasché P, Hagège AA, Scorsin M, et al. Myoblast transplantation for heart failure. Lancet. 2001;357:279–280[CrossRef][Web of Science][Medline]
  42. Koh GY, Klug MG, Soonpaa MH, Field LJ. Long-term survival of AT-1 cardiomyocyte grafts in syngeneic myocardium. Am J Physiol. 1993;264:H1727–H1733
  43. Tabibiazar R, Rockson SG. Angiogenesis and the ischemic heart. Eur Heart J. 2001;22:903–918[Free Full Text]
  44. Vale PR, Losordo DW, Milliken CE, et al. Randomized, singleblind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation. 2001;103:2138–2143[Abstract/Free Full Text]
  45. Kornowski R, Fuchs S, Leon MB, Epstein SE. Delivery strategies to achieve therapeutic myocardial angiogenesis. Circulation. 2000;101:454–458[Abstract/Free Full Text]
  46. Epstein SE, Kornowski R, Fuchs S, Dvorak HE. Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation. 2001;104:115–119[Free Full Text]
  47. Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: issues, problems, consensus. Circulation. 2000;102:e73–e86[Abstract/Free Full Text]
  48. Kalka C, Tehrani H, Laudenberg B, et al. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann Thorac Surg. 2000;70:829–834[Abstract/Free Full Text]
  49. Kawada T, Sakamoto A, Nakazawa M, et al. Morphological and physiological restorations of hereditary form of dilated cardiomyopathy by somatic gene therapy. Biochem Biophys Res Commun. 2001;284:431–435[CrossRef][Web of Science][Medline]
  50. Hajjar RJ, del Monte F, Matsui T, Rosenzweig A. Prospects for gene therapy for heart failure. Circ Res. 2000;86:616–621[Abstract/Free Full Text]
  51. del Monte F, Harding SE, Schmidt U, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 1999;100:2308–2311[Abstract/Free Full Text]
  52. Miyarnoto MI, del Monte F, Schmidt U, et al. Adenoviral gene transfer of SERCA2a improves left ventricular function in aorticbanded rats in transition to heart failure. Proc Natl Acad Sci USA. 2nd Edition. 2000. p. 793–798
  53. Weig HJ, Laugwitz KL, Moretti A, et al. Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors in vivo by ultrasound-guided injection or transcoronary delivery. Circulation. 2000;101:1578–1585[Abstract/Free Full Text]
  54. Marban E. Gene therapy for common acquired diseases of the heart. The sirens' song. Circulation. 2000;101:1498–1499[Free Full Text]
  55. Isner JM, Vale PR, Symes JF, Losordo DW. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res. 2001;89:389–400[Abstract/Free Full Text]
  56. Reinlib L, Field L. Cell transplantation as future therapy for cardiovascular disease? Circulation. 2000;101:182–187

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Menasché, P
Right arrow Articles by Desnos, M
Right arrow Search for Related Content
PubMed
Right arrow Articles by Menasché, P
Right arrow Articles by Desnos, M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?